PURPOSE: To evaluate the feasibility of hypofractionation with SIB in all settings in Germany to prepare a multicenter treatment comparison. METHODS: Eligible patients had histopathologically confirmed breast cancer operated by BCS. Patients received WBI 40.0 Gy in 16 fractions of 2.5 Gy. A SIB with 0.5 Gy per fraction was administered to the tumor bed, thereby giving 48.0 Gy in 16 fractions to the boost-PTV sparing heart, LAD, lung, contralateral breast. The primary study objective was feasibility, administration of specified dose in 16 fractions within 22-29 days with adherence to certain dose constraints (heart; LAD; contralateral breast); secondary endpoints were toxicity, QoL. RESULTS: 151 patients were recruited from 7 institutions between 07/11-10/12. 10 patients met exclusion criteria prior to irradiation. All but two patients (99%) received the prescribed dose in the PTVs. Adherence to dose constraints and time limits was achieved in 89% (95% CI 82% to 93%). 11 AE were reported in 10 patients; five related to concurrent endocrine therapy. Two of the AEs were related to radiotherapy: grade 3 hot flushes in two cases. QoL remained unchanged. CONCLUSION: Hypofractionation with a SIB is feasible and was well tolerated in this study.
PURPOSE: To evaluate the feasibility of hypofractionation with SIB in all settings in Germany to prepare a multicenter treatment comparison. METHODS: Eligible patients had histopathologically confirmed breast cancer operated by BCS. Patients received WBI 40.0 Gy in 16 fractions of 2.5 Gy. A SIB with 0.5 Gy per fraction was administered to the tumor bed, thereby giving 48.0 Gy in 16 fractions to the boost-PTV sparing heart, LAD, lung, contralateral breast. The primary study objective was feasibility, administration of specified dose in 16 fractions within 22-29 days with adherence to certain dose constraints (heart; LAD; contralateral breast); secondary endpoints were toxicity, QoL. RESULTS: 151 patients were recruited from 7 institutions between 07/11-10/12. 10 patients met exclusion criteria prior to irradiation. All but two patients (99%) received the prescribed dose in the PTVs. Adherence to dose constraints and time limits was achieved in 89% (95% CI 82% to 93%). 11 AE were reported in 10 patients; five related to concurrent endocrine therapy. Two of the AEs were related to radiotherapy: grade 3 hot flushes in two cases. QoL remained unchanged. CONCLUSION: Hypofractionation with a SIB is feasible and was well tolerated in this study.
Authors: D Azria; H Auvray; I Barillot; P Baumann; A Benyoucef; F Bons-Rosset; P Bontemps; C Bourgier; C Breton-Callu; D Cowen; J Cretin; B Delalande; F Denis; S Ellis; Z Gaci; J-M Hannoun-Lévy; A Hasbini; C Hennequin; J-L Lagrange; E Lartigau; I Latorzeff; M Le Blanc-Onfroy; I Lecouillard; C Lemanski; C Levy; P Maingon; C Marchal; A Monnier; O Pradier; S Racadot; P Romestaing; D Serin; J-M Simon; E Teyssier; A Tallet; A Tolédano; Y Belkacémi Journal: Cancer Radiother Date: 2008-08-13 Impact factor: 1.018
Authors: M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang Journal: Lancet Date: 2005-12-17 Impact factor: 79.321
Authors: Manjeet Chadha; Dan Vongtama; Patricia Friedmann; Celina Parris; Susan K Boolbol; Rudolph Woode; Louis B Harrison Journal: Clin Breast Cancer Date: 2011-11-06 Impact factor: 3.225
Authors: Timothy J Whelan; Jean-Philippe Pignol; Mark N Levine; Jim A Julian; Robert MacKenzie; Sameer Parpia; Wendy Shelley; Laval Grimard; Julie Bowen; Himu Lukka; Francisco Perera; Anthony Fyles; Ken Schneider; Sunil Gulavita; Carolyn Freeman Journal: N Engl J Med Date: 2010-02-11 Impact factor: 91.245
Authors: Hilde Van Parijs; Geertje Miedema; Vincent Vinh-Hung; Sylvia Verbanck; Nele Adriaenssens; Dirk Kerkhove; Truus Reynders; Daniel Schuermans; Katrien Leysen; Shane Hanon; Guy Van Camp; Walter Vincken; Guy Storme; Dirk Verellen; Mark De Ridder Journal: Radiat Oncol Date: 2012-06-01 Impact factor: 3.481
Authors: S Darby; P McGale; C Correa; C Taylor; R Arriagada; M Clarke; D Cutter; C Davies; M Ewertz; J Godwin; R Gray; L Pierce; T Whelan; Y Wang; R Peto Journal: Lancet Date: 2011-10-19 Impact factor: 79.321
Authors: F Sedlmayer; M-L Sautter-Bihl; W Budach; J Dunst; G Fastner; P Feyer; R Fietkau; W Haase; W Harms; R Souchon; F Wenz; R Sauer Journal: Strahlenther Onkol Date: 2013-10 Impact factor: 3.621
Authors: S M Bentzen; R K Agrawal; E G A Aird; J M Barrett; P J Barrett-Lee; S M Bentzen; J M Bliss; J Brown; J A Dewar; H J Dobbs; J S Haviland; P J Hoskin; P Hopwood; P A Lawton; B J Magee; J Mills; D A L Morgan; J R Owen; S Simmons; G Sumo; M A Sydenham; K Venables; J R Yarnold Journal: Lancet Date: 2008-03-19 Impact factor: 79.321
Authors: Pierfrancesco Franco; Domenico Cante; Piera Sciacero; Giuseppe Girelli; Maria Rosa La Porta; Umberto Ricardi Journal: Breast Care (Basel) Date: 2015-02 Impact factor: 2.860
Authors: Montserrat Pazos; Stephan Schönecker; Daniel Reitz; Paul Rogowski; Maximilian Niyazi; Filippo Alongi; Christiane Matuschek; Michael Braun; Nadia Harbeck; Claus Belka; Stefanie Corradini Journal: Breast Care (Basel) Date: 2018-05-24 Impact factor: 2.860
Authors: Harriet Eldredge-Hindy; Jianmin Pan; Shesh N Rai; Leonid B Reshko; Anthony Dragun; Elizabeth C Riley; Kelly M McMasters; Nicolas Ajkay Journal: Ann Surg Oncol Date: 2021-03-18 Impact factor: 5.344